Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
In non–small cell lung cancer (NSCLC), response to immune checkpoint blockade (ICB) is
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …
[HTML][HTML] Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
S Hiltbrunner, L Cords, S Kasser, SN Freiberger… - Nature …, 2023 - nature.com
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell
lung cancer (NSCLC), however, some of the patients develop resistance following initial …
lung cancer (NSCLC), however, some of the patients develop resistance following initial …
[HTML][HTML] Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy
C Pfirschke, C Engblom, S Rickelt, V Cortez-Retamozo… - Immunity, 2016 - cell.com
Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …
[HTML][HTML] Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer
The efficacy of immune checkpoint blockade (ICB) varies greatly among metastatic non-
small cell lung cancer (NSCLC) patients. Loss of heterozygosity at the HLA-I locus (HLA …
small cell lung cancer (NSCLC) patients. Loss of heterozygosity at the HLA-I locus (HLA …
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
M van Gulijk, A van Krimpen, S Schetters… - Science …, 2023 - science.org
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types,
most patients with cancer do not respond well. Furthermore, in patients for whom ICB is …
most patients with cancer do not respond well. Furthermore, in patients for whom ICB is …
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity
RA Watson, O Tong, R Cooper, CA Taylor… - Science …, 2021 - science.org
The antitumor action of immune checkpoint blockade (ICB) is primarily mediated by CD8+ T
cells. How sensitivity to ICB varies across CD8+ T cell subsets and clonotypes and the …
cells. How sensitivity to ICB varies across CD8+ T cell subsets and clonotypes and the …
[HTML][HTML] A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
The biological determinants of sensitivity and resistance to immune checkpoint blockers are
not completely understood. To elucidate the role of intratumoral T-cells and their association …
not completely understood. To elucidate the role of intratumoral T-cells and their association …
[HTML][HTML] Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with …
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with …
[HTML][HTML] Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade
CCS Pai, JT Huang, X Lu, DM Simons, C Park… - Immunity, 2019 - cell.com
Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …
A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade
Immune checkpoint blockade (ICB) is efficacious in many diverse cancer types, but not all
patients respond. It is important to understand the mechanisms driving resistance to these …
patients respond. It is important to understand the mechanisms driving resistance to these …
相关搜索
- checkpoint blockade therapeutic resistance
- checkpoint blockade cell activity
- lung cancer acquired resistance
- lung cancer checkpoint inhibitors
- checkpoint blockade patient response
- checkpoint blockade interferon γ
- checkpoint blockade clonal deletion
- checkpoint blockade transcriptional programs
- checkpoint blockade proliferative potential
- cell phenotype acquired resistance
- therapy resistance cell activity
- checkpoint inhibitors acquired resistance
- checkpoint blockade pd l1
- checkpoint blockade therapy resistance